<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Mainz Biomed N.v. — News on 6ix</title>
    <link>https://6ix.com/company/mainz-biomed-nv</link>
    <description>Latest news and press releases for Mainz Biomed N.v. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 13 Mar 2026 11:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/mainz-biomed-nv" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d77d0751cc36e475341057.webp</url>
      <title>Mainz Biomed N.v.</title>
      <link>https://6ix.com/company/mainz-biomed-nv</link>
    </image>
    <item>
      <title>Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/quantum-cyber-fka-mainz-biomed-announces-stock-ticker-symbol-change-to-nasdaq-qucy-111</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/quantum-cyber-fka-mainz-biomed-announces-stock-ticker-symbol-change-to-nasdaq-qucy-111</guid>
      <pubDate>Fri, 13 Mar 2026 11:30:00 GMT</pubDate>
      <description>BERKELEY, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber, today announced, effective upon the commencement of trading on March 12, 2026 (U.S. Eastern Time), it officially changed its ticker symbol to &quot;QUCY&quot; on the Nasdaq Capital Market. Further the Company’s name will change to Quantum Cyber N.V. (“Quantum” or “Company”) effective with a general meeting of shareholders planned for April 2026. The corporate name change and stock ticker</description>
    </item>
    <item>
      <title>Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-appointment-of-robert-liscouski-as-chairman-of-the-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-appointment-of-robert-liscouski-as-chairman-of-the-board-of-directors</guid>
      <pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
      <description>Company Also Announces New Name: Quantum Cyber and Change in Nasdaq Ticker symbol BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.</description>
    </item>
    <item>
      <title>Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-60-usd-million-private-placement-and-strategic-update</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-60-usd-million-private-placement-and-strategic-update</guid>
      <pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
      <description>Company to Focus on Pancreatic Cancer Detection Business in the U.S., Strategic Asset Sales and Future Strategic Transaction BERKELEY, Calif. and MAINZ,</description>
    </item>
    <item>
      <title>Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-to-present-results-of-pancreatic-cancer-verification-study-at-aacr-2026-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-to-present-results-of-pancreatic-cancer-verification-study-at-aacr-2026-annual-meeting</guid>
      <pubDate>Wed, 14 Jan 2026 05:00:00 GMT</pubDate>
      <description>First data on blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and intraductal papillary mucinous neoplasms (IPMN)</description>
    </item>
    <item>
      <title>Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-and-oncovanguard8-enter-into-agreement-to-bring-coloalert-to-south-america</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-and-oncovanguard8-enter-into-agreement-to-bring-coloalert-to-south-america</guid>
      <pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
      <description>OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and Ecuador BERKELEY,</description>
    </item>
    <item>
      <title>Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-reports-topline-results-from-feasibility-study-of-biomarker-panel-in-pancreatic-cancer-project</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-reports-topline-results-from-feasibility-study-of-biomarker-panel-in-pancreatic-cancer-project</guid>
      <pubDate>Wed, 08 Oct 2025 04:00:00 GMT</pubDate>
      <description>Study Demonstrated a Sensitivity of 100% and Specificity of 95% Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics</description>
    </item>
    <item>
      <title>Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-commercial-launch-of-coloalertr-in-switzerland</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-commercial-launch-of-coloalertr-in-switzerland</guid>
      <pubDate>Tue, 23 Sep 2025 04:00:00 GMT</pubDate>
      <description>Company Provides Update on eAArly DETECT 2 Study BERKELEY, Calif. and MAINZ, Germany, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ)</description>
    </item>
    <item>
      <title>Mainz Biomed Announces Registration of ColoAlert in the United Kingdom</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-registration-of-coloalert-in-the-united-kingdom</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-registration-of-coloalert-in-the-united-kingdom</guid>
      <pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
      <description>BERKELEY, Calif. and MAINZ, Germany, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular</description>
    </item>
    <item>
      <title>Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-receives-swiss-regulatory-approval-to-market-coloalertr</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-receives-swiss-regulatory-approval-to-market-coloalertr</guid>
      <pubDate>Wed, 13 Aug 2025 04:00:00 GMT</pubDate>
      <description>BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics</description>
    </item>
    <item>
      <title>Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-pricing-of-dollar30-million-follow-on-offering-of-ordinary-shares-and-warrants</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-pricing-of-dollar30-million-follow-on-offering-of-ordinary-shares-and-warrants</guid>
      <pubDate>Mon, 04 Aug 2025 04:00:00 GMT</pubDate>
      <description>BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics</description>
    </item>
    <item>
      <title>Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-and-care-conclude-cooperation-agreement-for-joint-care-concept-for-health-insurance-companies</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-and-care-conclude-cooperation-agreement-for-joint-care-concept-for-health-insurance-companies</guid>
      <pubDate>Wed, 23 Jul 2025 04:00:00 GMT</pubDate>
      <description>CARE currently cooperates with 19 health insurance companies in Germany in the field of colorectal cancer screening BERKELEY, Calif. and MAINZ, Germany, July</description>
    </item>
    <item>
      <title>Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-half-year-2025-update-accelerating-fda-pathway-for-nextgen-colorectal-cancer-screening-and-expansion-with-pancreatic-cancer-screening-acquisition</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-half-year-2025-update-accelerating-fda-pathway-for-nextgen-colorectal-cancer-screening-and-expansion-with-pancreatic-cancer-screening-acquisition</guid>
      <pubDate>Tue, 15 Jul 2025 04:00:00 GMT</pubDate>
      <description>Company Advances its Progress toward FDA Premarket Approval Study for its Next Generation Colorectal Cancer Screening Product and Makes a Strategic</description>
    </item>
    <item>
      <title>Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-secures-public-funding-to-advance-innovative-pancreatic-cancer-screening-test</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-secures-public-funding-to-advance-innovative-pancreatic-cancer-screening-test</guid>
      <pubDate>Wed, 25 Jun 2025 04:00:00 GMT</pubDate>
      <description>BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics</description>
    </item>
    <item>
      <title>Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-initiates-feasibility-study-of-biomarker-panel-in-pancreatic-cancer-project</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-initiates-feasibility-study-of-biomarker-panel-in-pancreatic-cancer-project</guid>
      <pubDate>Tue, 10 Jun 2025 04:00:00 GMT</pubDate>
      <description>Study is Intended to Verify Previous Discovery Results Demonstrating Sensitivity of 95% and Specificity of 98% BERKELEY, Calif. and MAINZ, Germany, June 10,</description>
    </item>
    <item>
      <title>Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-pricing-of-dollar40-million-follow-on-offering-of-ordinary-shares-and-warrants</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-pricing-of-dollar40-million-follow-on-offering-of-ordinary-shares-and-warrants</guid>
      <pubDate>Mon, 19 May 2025 04:00:00 GMT</pubDate>
      <description>BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics</description>
    </item>
    <item>
      <title>Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-interim-read-out-for-its-eaarly-detect-2-clinical-study</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-announces-interim-read-out-for-its-eaarly-detect-2-clinical-study</guid>
      <pubDate>Fri, 16 May 2025 04:00:00 GMT</pubDate>
      <description>Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial</description>
    </item>
    <item>
      <title>Mainz Biomed Enters into Technology Partnership with EDX Medical Group</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-enters-into-technology-partnership-with-edx-medical-group</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-enters-into-technology-partnership-with-edx-medical-group</guid>
      <pubDate>Tue, 29 Apr 2025 04:00:00 GMT</pubDate>
      <description>BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular</description>
    </item>
    <item>
      <title>Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-provides-first-quarter-2025-corporate-update-and-path-to-fda-premarket-approval</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-provides-first-quarter-2025-corporate-update-and-path-to-fda-premarket-approval</guid>
      <pubDate>Mon, 28 Apr 2025 04:00:00 GMT</pubDate>
      <description>BERKELEY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic</description>
    </item>
    <item>
      <title>Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-reports-2024-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-reports-2024-financial-results-and-provides-corporate-update</guid>
      <pubDate>Tue, 01 Apr 2025 04:00:00 GMT</pubDate>
      <description>Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by 30% and net loss by 18%,</description>
    </item>
    <item>
      <title>Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study</title>
      <link>https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-enrolls-first-patient-in-its-eaarly-detect-2-clinical-study</link>
      <guid isPermaLink="true">https://6ix.com/company/mainz-biomed-nv/news/mainz-biomed-enrolls-first-patient-in-its-eaarly-detect-2-clinical-study</guid>
      <pubDate>Thu, 27 Mar 2025 04:00:00 GMT</pubDate>
      <description>2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in</description>
    </item>
  </channel>
</rss>